Anti-Neoplastic Therapy Market: By Agent Type (Alkylating and Alkylating-Like Agents, Antimetabolites, Antitumor Antibiotics, Plant Alkaloids, Hormonal Agents, and Miscellaneous Agents) By Product Type (Chemotherapeutic Agents, Immunotherapeutic Agents, and Personalized Medicine), By Cancer Type (Bladder Cancer, Prostate Cancer, Blood Cancer, Melanoma, Breast Cancer, Throat Cancer, Kidney Cancer, Uterine Cancer, Lungs Cancer, and Other), By End Users (Hospitals, Clinics, Research Institutes, Cancer Rehabilitation Centers, and Others) And Geography  

Anti-Neoplastic Therapy Market size is expected to be valued at USD 134 billion in 2022 which is expected to grow at a CAGR of 7.8% from 2023-2029. Anti-neoplastic therapy is defined as a process that is used to cure infection imposed by neoplastic diseases such as malignant or benign tumors by using various types of modern medications and treatments such as cytotoxic drugs, oncology drugs, anticancer drugs, and immunotherapies. Neoplasms are tumor cells that grow indefinitely and cause neoplastic disease. One of the major causes of such types of diseases is changes in the DNA strand of the patient that leads to altered function of genes and eventually, cause some type of cancer. Rising research in the biotechnology and pharmaceutical domains for the discovery of new drugs can lead to the growth of the anti-neoplastic therapy market. Moreover, the high prevalence of cancer disease, technological advancements in drug development, and discoveries are some primary factors that can boost the global anti-neoplastic therapy market. Apart from these, various government interventions, high frequencies of cardiac attacks, and technological progress towards the improvement of human healthcare also accelerate the market in the future. However, some factors such as the absence of skilled professionals and the high cost of treatment can restrain the growth of the market. Increasing innovation in the sector of personalized medicines, and government affords to encourage control and prevention practices have created an opportunity for the growth of the global anti-neoplastic therapy market. Moreover, the competitive landscape and rising development in anti-neoplastic therapy are expected to produce lucrative opportunities for the global market share.

Anti-Neoplastic Therapy Market Key Developments:

• In November 2021, LYT-200, a clinical therapeutic human IgG4 monoclonal antibody used for the treatment of pancreatic cancer developed by PureTech was approved by FDA as an Orphan Drug
• In October 2021, Astra-tine-11, a gold nanoparticle utilizing system used for targeted cancer radiations, was developed by scientists of a Japanese University